GB2068731A - Naphthyridine derivative useful in therapy and pharmaceutical compositions containing the same - Google Patents
Naphthyridine derivative useful in therapy and pharmaceutical compositions containing the same Download PDFInfo
- Publication number
- GB2068731A GB2068731A GB8104135A GB8104135A GB2068731A GB 2068731 A GB2068731 A GB 2068731A GB 8104135 A GB8104135 A GB 8104135A GB 8104135 A GB8104135 A GB 8104135A GB 2068731 A GB2068731 A GB 2068731A
- Authority
- GB
- United Kingdom
- Prior art keywords
- compound
- therapy
- formula
- pharmaceutical compositions
- same
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 8
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 6
- 150000005054 naphthyridines Chemical class 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 206010000117 Abnormal behaviour Diseases 0.000 claims abstract description 4
- 208000026680 Metabolic Brain disease Diseases 0.000 claims abstract description 4
- 230000003970 cerebral vascular damage Effects 0.000 claims abstract description 4
- 208000009999 tuberous sclerosis Diseases 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 231100000252 nontoxic Toxicity 0.000 claims description 4
- 230000003000 nontoxic effect Effects 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008298 dragée Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229940102223 injectable solution Drugs 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 229940102213 injectable suspension Drugs 0.000 claims 1
- 239000000969 carrier Substances 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000155 melt Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- XYGBKMMCQDZQOZ-UHFFFAOYSA-M sodium;4-hydroxybutanoate Chemical compound [Na+].OCCCC([O-])=O XYGBKMMCQDZQOZ-UHFFFAOYSA-M 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- MUQUYTSLDVKIOF-CHJKCJHBSA-N alcuronium Chemical compound C/1([C@@H]23)=C\N([C@H]4\5)C6=CC=CC=C6[C@]4(CC[N@@+]4(CC=C)C\C6=C\CO)[C@@H]4C[C@@H]6C/5=C/N3C3=CC=CC=C3[C@@]22CC[N@@+]3(CC=C)C/C(=C/CO)[C@@H]\1C[C@H]32 MUQUYTSLDVKIOF-CHJKCJHBSA-N 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 210000004894 snout Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940072358 xylocaine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8003011A FR2475394A1 (fr) | 1980-02-12 | 1980-02-12 | Compositions pharmaceutiques contenant l'hexahydro-1, 2, 3, 3a, 4, 5, 6h indolo (3, 2, 1 - d. e) (1, 5) naphtyridinone - 6 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB2068731A true GB2068731A (en) | 1981-08-19 |
Family
ID=9238471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB8104135A Withdrawn GB2068731A (en) | 1980-02-12 | 1981-02-11 | Naphthyridine derivative useful in therapy and pharmaceutical compositions containing the same |
Country Status (11)
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4617305A (en) * | 1983-02-25 | 1986-10-14 | Omnichem, S.A. | 4-alkylindolonaphthyridines and their therapeutical application |
| US5189041A (en) * | 1990-11-16 | 1993-02-23 | Syntex (U.S.A.) Inc. | Tricyclic 5-ht3 receptor antagonists |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1329597C (en) * | 1986-12-22 | 1994-05-17 | Dagmar Hoeltje | Derivatives of tetrahydropyrido[1,2-a]indole |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2358146A1 (fr) * | 1976-04-13 | 1978-02-10 | Synthelabo | Derives de la tetrahydro-1,2,3,3a indolo(3,2,1-de) (1,5)naphtyridine |
-
1980
- 1980-02-12 FR FR8003011A patent/FR2475394A1/fr active Granted
-
1981
- 1981-02-10 AU AU67145/81A patent/AU6714581A/en not_active Abandoned
- 1981-02-11 DE DE19813104884 patent/DE3104884A1/de active Pending
- 1981-02-11 LU LU83128A patent/LU83128A1/fr unknown
- 1981-02-11 BE BE0/203762A patent/BE887468A/fr unknown
- 1981-02-11 IL IL62114A patent/IL62114A0/xx unknown
- 1981-02-11 GB GB8104135A patent/GB2068731A/en not_active Withdrawn
- 1981-02-11 ZA ZA00810919A patent/ZA81919B/xx unknown
- 1981-02-11 IT IT19667/81A patent/IT1135422B/it active
- 1981-02-11 NL NL8100645A patent/NL8100645A/nl not_active Application Discontinuation
- 1981-02-12 JP JP2000581A patent/JPS56127313A/ja active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4617305A (en) * | 1983-02-25 | 1986-10-14 | Omnichem, S.A. | 4-alkylindolonaphthyridines and their therapeutical application |
| US5189041A (en) * | 1990-11-16 | 1993-02-23 | Syntex (U.S.A.) Inc. | Tricyclic 5-ht3 receptor antagonists |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA81919B (en) | 1982-03-31 |
| DE3104884A1 (de) | 1982-01-14 |
| FR2475394B1 (enrdf_load_stackoverflow) | 1982-05-21 |
| FR2475394A1 (fr) | 1981-08-14 |
| NL8100645A (nl) | 1981-09-01 |
| IL62114A0 (en) | 1981-03-31 |
| LU83128A1 (fr) | 1982-09-10 |
| IT1135422B (it) | 1986-08-20 |
| JPS56127313A (en) | 1981-10-06 |
| IT8119667A0 (it) | 1981-02-11 |
| AU6714581A (en) | 1981-08-20 |
| BE887468A (fr) | 1981-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IE47798B1 (en) | Substituted ortho-anisamides,methods of preparing them,compositions containing them and their application as psychotropic agents | |
| CS247159B2 (en) | Method of cis,endo-2-azabicyclo(3,3,1) octal-3-carboxyl acid's derivatives production | |
| US3987177A (en) | Vincaminic acid esters | |
| KR960003327B1 (ko) | 디클로페낙과 환상 유기염기와의 염 및 이를 함유한 약학적 조성물 | |
| US4767758A (en) | Pharmaceutical compositions containing thiophene compounds, and new thiophene compounds | |
| HU204053B (en) | Process for producing eseroline derivatives and pharmaceutical compositions comprising such compounds as active ingredient | |
| JPS6020394B2 (ja) | 抗生物質の製造方法 | |
| GB2068731A (en) | Naphthyridine derivative useful in therapy and pharmaceutical compositions containing the same | |
| US3940387A (en) | Yohimbine derivatives, process for their preparation and their applications | |
| US4137326A (en) | Use of magnesium monospartate hydrochloride complex | |
| NO146777B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive 6h-indolo (3,2,1-de)-(1,5)-naftyridinderivater | |
| PT92591B (pt) | Processo para a preparacao de aciloxipropanolaminas com accao bloqueadora beta--adrenergica e de composicoes farmaceuticas que as contem | |
| FR2610932A1 (fr) | Nouvel acide piperazinecarboxylique, sa preparation et son utilisation comme medicament | |
| FI61182C (fi) | Foerfarande foer framstaellning av farmaceutiskt aktiva butylaminderivat | |
| SU1036249A3 (ru) | Способ получени производных 5,6,8,9-тетрагидро-7 @ -дибенз / @ / азонина или их солей | |
| US7354949B2 (en) | Therapeutic agent for bladder irritative symptoms associated with benign prostatic hyperplasia | |
| JP2004529982A (ja) | 逆流症に有効な新規な化合物 | |
| JP2954989B2 (ja) | ビスフェノール誘導体での真性糖尿病処置法 | |
| CA1162544A (en) | Naphthyridine derivatives | |
| SK695188A3 (en) | Enolether amide 1,1-dioxo-6-chloro-4-hydroxy-2-methyl-n-(2- -pyridyl)-2h-thieno (2,3-e)-1,2-thiazine-3-carboxylic acid, method of its production and pharmaceutical agent | |
| US3696198A (en) | Treatment of anoxia with 3,5-dialkyl hydantoins | |
| US5489609A (en) | 2-aminoethanesulfonic acid zinc complex compound | |
| US3772378A (en) | 7-oxo-benzocycloheptene acetic acids | |
| DE2819457B2 (de) | L- oder DL-Phenylglycin-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| US4024259A (en) | 3-Anilino-2,4-diazabicyclo[3.2.1]octenes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |